Coordinated the CAP accreditation project, which was initiated in 2011 for the GSC’s clinical pipeline involving ABI capillary sequencing instruments for testing BRCA1/BRCA2 breast cancer genes. Later in 2013, the clinical pipeline expanded to 16 gene panel testing with Illumina Sequencers, and now the GSC provides targeted capture panel testing for three cancer panels: hereditary cancer panel, onco panel and myeloid panel. The clinical pipeline is accredited by CAP every two years, ensuring the highest quality program is maintained for the clinical testing program at the GSC. The stringent CAP accreditation program involves a 2 year external audit cycle in which the auditors review over 1500 quality and technical requirements before they recommend accreditation for the GSC.